- A novel gene expression signature called OTTA-SPOT (Ovarian Tumor Tissue Analysis Consortium–Stratified Prognosis of Ovarian Tumors) could improve prognostication in patients with high-grade serous ovarian cancer.
Why this matters
- Prognostic gene expression signature tests are available for other cancers, such as breast cancer, but none are available for ovarian cancer.
- A 101-gene expression signature was developed and validated using pretreatment tumor tissue from 3769 women with high-grade serous ovarian cancer treated on 21 studies.
- Funding: National Institutes of Health/National Cancer Institute; Canadian Institutes for Health Research; Department of Defense Ovarian Cancer Research Program.
- Adding the signature to age and stage alone improved the prediction of 2- and 5-year OS.
- The area under the curve increased from 0.61 to 0.69 for 2-year OS and from 0.62 to 0.75 for 5-year OS (nonoverlapping 95% CIs).
- Each standard deviation increase in the gene expression score was associated with a more than doubling of the mortality risk (HR, 2.35; P<.001>
- OS by gene expression score quintiles: 9.5, 5.4, 3.8, 3.2, and 2.3 years for patients in the first, second, third, fourth, and fifth quintiles, respectively.
- Heterogeneity by ancestry or ethnicity was not in the scope of the study.